2. pcr positive in sample collected \>/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking \>24 hours, etc.) and progressive disease suggestive of ongoing sars-cov-2 infection. 6. illness of any duration, and at least one of the following: 1. radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or 2. spo2 \< / = 94% on room air, or 3. requiring supplemental oxygen, or 4. requiring mechanical ventilation. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 8. agrees to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 through day 29.

2. pcr positive in sample collected \>/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking \>24 hours, etc.) and progressive disease suggestive of ongoing sars-cov-2 infection. 6. illness of any duration, and at least one of the following: 1. radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or 2. spo2 \< / = 94% on room air, or 3. requiring supplemental oxygen, or 4. requiring mechanical ventilation. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 8. agrees to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 through day 29.

pcr positive in sample collected >/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) and progressive disease suggestive of ongoing sars-cov-2 infection. illness of any duration, and at least one of the following: radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or spo2 < / = 94% on room air, or requiring supplemental oxygen, or requiring mechanical ventilation. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. agrees to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 through day 29.

pcr positive in sample collected >/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) and progressive disease suggestive of ongoing sars-cov-2 infection. illness of any duration, and at least one of the following: radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or spo2 < / = 94% on room air, or requiring supplemental oxygen, or requiring mechanical ventilation. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. agrees to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 through day 29.

alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal. estimated glomerular filtration rate (egfr) < 30 ml/min (including patients receiving hemodialysis or hemofiltration). pregnancy or breast feeding. anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours. allergy to any study medication.

alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal. estimated glomerular filtration rate (egfr) < 30 ml/min (including patients receiving hemodialysis or hemofiltration). pregnancy or breast feeding. anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours. allergy to any study medication.

1. alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal. 2. estimated glomerular filtration rate (egfr) < 30 ml/min (including patients receiving hemodialysis or hemofiltration). 3. pregnancy or breast feeding. 4. anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours. 5. allergy to any study medication.

1. alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal. 2. estimated glomerular filtration rate (egfr) < 30 ml/min (including patients receiving hemodialysis or hemofiltration). 3. pregnancy or breast feeding. 4. anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours. 5. allergy to any study medication.